Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback